Slama M A, Komajda M
APNET, Service de Réanimation polyvalente, Hôpital Nord, Amiens.
Presse Med. 1996 Dec 14;25(39):1961-6.
Mortality in patients with congestive heart failure has been assessed in several large scale multicentric studies, confirming the therapeutic effect of certain treatments and raising questions as to the efficacy of other, sometimes new propositions. Conversion enzyme inhibitors are currently considered to be the first line treatment for heart failure because of their beneficial effect on mortality figures and their capacity to prevent aggravation. These drugs should always be prescribed for patients without contraindications, together with diuretics when signs of congestion develop, and digitalis in case of non-response, then finally nitroglycerin. Debate is still open on the effect of beta-blockers and amiodarone which should be reserved for use by specialists since it has not been definitely proven that they can lengthen survival time. Certain other drugs have given disappointing results compared with early expectations: direct vasodilators, positive inotrops (with the possible exception of vesnarinone), and class Ic antiarrhythmics. Finally several drugs in the development or research stage may prove to be effective in improving heart function, intermediary criteria and, most importantly, survival.
在多项大规模多中心研究中对充血性心力衰竭患者的死亡率进行了评估,证实了某些治疗方法的疗效,并对其他一些(有时是新提出的)治疗方法的有效性提出了疑问。由于转换酶抑制剂对死亡率有有益影响且有预防病情加重的能力,目前被认为是心力衰竭的一线治疗药物。对于没有禁忌证的患者,应始终开具这些药物,当出现充血迹象时,可同时使用利尿剂,如无反应则使用洋地黄,最后使用硝酸甘油。β受体阻滞剂和胺碘酮的效果仍存在争议,由于尚未明确证明它们能延长生存时间,应由专科医生使用。与早期预期相比,某些其他药物的结果令人失望:直接血管扩张剂、正性肌力药物(可能除了维司力农)和Ic类抗心律失常药物。最后,几种处于研发或研究阶段的药物可能被证明对改善心脏功能、中间指标以及最重要的生存有效。